Antares Pharma, Inc. [NASDAQ:ATRS]: Analyst Rating and Earnings
Stock traders often pay close attention what Wall Street analysts have to say about a potential investment. The average 12-month price forecast for this stock is $5.54, with the high estimate being $8.00, the low estimate being $4.50 and the median estimate amounting to $5.13. This is compared to its latest closing price of $3.06.
Keep an eye out for the next scheduled publication date for this company’s financial results, which are expected to be released on Tue 12 Mar (In 63 Days).
Fundamental Analysis of Antares Pharma, Inc. [ATRS]
Now let’s turn to look at profitability: with a current Operating Margin for Antares Pharma, Inc. [ATRS] sitting at -30.18 and its Gross Margin at +48.58, this company’s Net Margin is now -27.80%. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -31.75, and its Return on Invested Capital has reached -28.20%. its Return on Equity is -42.51, and its Return on Assets is -23.81. These metrics suggest that this Antares Pharma, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Antares Pharma, Inc. [ATRS] has generated a Total Debt to Total Equity ratio of 74.10. Similarly, its Total Debt to Total Capital is 42.56, while its Total Debt to Total Assets stands at 33.44. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 74.10, and its Long-Term Debt to Total Capital is 42.56. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.
What about valuation? This company’s Enterprise Value to EBITDA is -29.73. The Enterprise Value to Sales for this firm is now 7.26, and its Total Debt to Enterprise Value stands at 0.08. Antares Pharma, Inc. [ATRS] has a Price to Book Ratio of 9.29. These metrics all suggest that Antares Pharma, Inc. is more likely to generate a positive ROI.
Shifting the focus to workforce efficiency, Antares Pharma, Inc. [ATRS] earns $491,126 for each employee under its payroll. Income works out to -$150,838 per employee. Similarly, this company’s Receivables Turnover is 5.20 and its Total Asset Turnover is 0.78. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.91 and its Current Ratio is 3.50. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: Antares Pharma, Inc. [ATRS] has 152.70M shares outstanding, amounting to a total market cap of $467.26M. Its stock price has been found in the range of 1.85 to 3.93. At its current price, it has moved by -20.99% from its 52-week high, and it has moved 67.84% from its 52-week low.
This stock’s Beta value is currently 0.95, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 53.83. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Antares Pharma, Inc. [ATRS] a Reliable Buy?
Antares Pharma, Inc. [ATRS] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.